Linaclotide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Constipation
Conditions
Functional Constipation, Irritable Bowel Syndrome With Constipation
Trial Timeline
Oct 1, 2019 → May 29, 2024
NCT ID
NCT04026113About Linaclotide + Placebo
Linaclotide + Placebo is a phase 3 stage product being developed by AbbVie for Functional Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT04026113. Target conditions include Functional Constipation, Irritable Bowel Syndrome With Constipation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05760313 | Phase 2 | Completed |
| NCT04026113 | Phase 3 | Completed |
Competing Products
20 competing products in Functional Constipation